Fig. 6
From: Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling
Cost-effectiveness acceptability curve and frontier for strategies with the highest incremental net monetary benefit. a Cost-effectiveness acceptability curve. b Cost-effectiveness acceptability frontier. NB: X axis is limited to 1000 USD per DALY averted. Strategies are vaccinating children 6–23 months (strategy I), 2–5 years (strategy II) and 6–14 years (strategy III) with either the SH influenza vaccine (Strategy A) or NH vaccine (Strategy B) or both (Strategy C: twice yearly 3-month vaccination periods, or Strategy D: year-round vaccination)